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Abstract  
 
Background 
Migraine is a debilitating neurological disorder affecting approximately 12% of the 
Caucasian population. There are two main sub-types of migraine, migraine without aura 
(MO) and migraine with aura (MA). Migraine exhibits varied phenotypic expression with 
sufferers experiencing a range of neurological and other symptoms. It is likely that 
multiple susceptibility genes play a role in this varied phenotypic expression, thus 
investigation of genotype-phenotype relationships may provide valuable insights into the 
role of susceptibility genes in this disorder.  
Methods 
This study investigated the links between migraine susceptibility genes, 
methylenetetrahydrofolate reductase (MTHFR) and angiotensin converting enzyme 
(ACE), and clinical manifestation through statistical analyses.  
Results 
The result showed that for the MTHFR genotypes, there was a statistically significant 
correlation with the TT homozygous genotype and visual disturbances, unilateral head 
pain and physical activity discomforts. It was also found that bilateral head pain was 
associated with the male gender. 
Conclusion 
From these study results, it is plausible to state that MTHFR genotypes affect the 
phenotypic expression of migraine disease manifestation. (167 words) 
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Introduction  
 
Migraine is a complex, multifactorial disorder, characterised by photophobia and 
phonophobia, nausea and vomiting, neurological disturbances and severe recurrent 
headache. This debilitating disorder affects approximately 12% of the Caucasian 
population (1). A number of susceptibility genes for migraine have been identified, 
including methylenetetrahydrofolate reductase (MTHFR) and angiotensin converting 
enzyme (ACE) (2-7). These genes have been identified via candidate association studies. 
At present, there are no biochemical tests to confirm the diagnosis of migraine; rather 
diagnosis is usually achieved by matching the patient’s clinical manifestations to the 
classifications outlined by the International Headache Society’s (IHS) International 
Classification of Headache Disorders. The Headache Classification Subcommittee of the 
IHS defines two main classes of migraine, migraine with aura (MA) and migraine without 
aura (MO). MO is the commonest subtype of migraine. Whilst the two subtypes have 
significant symptomatic overlap, individuals with MA experience a distinct phase of 
neurological disturbances known as an “aura”, that usually precede the headache phase of 
an attack (8). Despite rigorous investigations into the pathophysiology of migraine, it 
remains largely an enigma. This investigation is further challenged by the complex nature 
of the disorder, in which multiple susceptibility genes and environmental triggers play a 
role, suggesting the involvement of multiple proteins (eg. enzymes and hormones), 
receptors and systems.  
 
The human MTHFR gene has been mapped to chromosome 1p36.3. It has 11 exons, and 
spans approximately 17kb (9, 10).  MTHFR catalyses the NAPDH-dependent conversion 
of 5, 10-methylenetetrahydrofolate (CH2-THF) to 5-methyltetrahydrofolate (CH3-THF), 
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the principal circulatory form of folate and a cofactor for methylation of homocysteine to 
methionine. The conversion of homocysteine to methionine is regulated by the vitamin 
B12 (folate)-dependent methionine synthase. Methionine is then converted to 5-adenosyl 
methionine (SAM), where it acts as a methyl donor in numerous reactions, including the 
methylation of DNA, RNA, hormones and lipids. MTHFR is a key enzyme in purine and 
pyrimidine metabolism, as 5, 10-methylenetetrahydrofolate is required for nucleic acid 
synthesis. Hereditary deficiency of MTHFR, causes the most common inborn errors of 
metabolism in folic acid metabolism. MTHFR is a key reagent in the synthesis of 
methionine, and its metabolite SAM which is critical for methylation reactions in the 
central nervous system. Undermethylation leads to the activation of more genes, 
overexpression of unnecessary genes, sensitising the individual to the environment, and 
potentially causing a migraine attack (2). Folate appears to play an important role in 
methylation, as deficiencies in folate can exacerbate the process in susceptible individuals 
(2, 5). Studies in genotypic-phenotypic correlation of the MTHFR gene emphasise the 
need to consider variants of MTHFR as a contributor to neurologic diseases in humans 
(9). It is proposed that homocysteine acts as an excitatory amino acid in migraine 
pathophysiology, either by causing vasodilation of cerebral blood vessels or temporary 
thrombosis of cerebral blood vessels, allowing less oxygen into the brain (2, 5). 
Homocysteine also has a role in the synthesis of neurotransmitters such as serotonin, 
noradrenaline and dopamine. Individuals undergoing a migraine attack experience 
autonomic nervous system dysfunction and altered levels of neurotransmitters. As 
individuals carrying the C677T mutation have decreased MTHFR enzyme activity, their 
neurotransmitter production is also likely decreased, making them susceptible to migraine 
attacks (2). 
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A common variant of the MTHFR gene is C677T, which has been shown to demonstrate 
autosomal recessive inheritance (11). The point mutation causes alanine to be replaced by 
valine in the MTFHR enzyme. Individuals homozygous for the mutant Ala to Val 
substitution genotype express thermolabile enzymes with approximately 30% of the mean 
activity MTHFR enzyme levels, compared to individuals without the substitution allele. 
Heterozygotes have a mean activity level of 65% of the wild-type homozygotes. The 
mutant allele causes mild elevations in plasma homocysteine levels especially when folate 
intake is low (12, 13).  
 
ACE is a dipeptidyl carboxypeptidase that is expressed in many tissues, including 
vascular and endothelial cells and regulates blood pressure and electrolyte balance (14). It 
is the rate limiting enzyme of the renin angiotensin system and converts angiotensin I into 
angiotensin II, a potent vasopressor and aldosterone-stimulating peptide. ACE can also 
inactivate bradykinin, a potent vasodilator. The ACE gene has been mapped to 17q23 and 
has two polymorphic alleles, insertion I, and the deletion D of 287bp Alu sequence within 
intron 16 (15). The variance in plasma ACE levels is due in part to the I/D polymorphism 
(16), and has been associated with myocardial infarction and ischaemic stroke (14, 15). 
The Alu marker however, does not seem to have a functional effect other than the control 
of plasma ACE levels. There have been interesting results published on the effects of ACE 
DD genotype’s link to migraine. In an Italian study, DD was found to be correlated with 
migraine without aura and contributed to increased migraine attacks (17). More recently, 
the DD genotype was reported as a genetic risk factor for MA in a Japanese study group 
(18). Lea et al found that ACE and MTHFR act in combination to increase migraine risk 
with the ACE D allele acting in a dominant fashion (7). 
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The role of ACE in migraine pathophysiology is mainly ascertained through the actions of 
pharmacological effects. ACE inhibitors are an effective migraine prophylactic (19-21). 
ACE has a pivotal role in dopamine regulation. Angiotensin II binds to the angiotensin II 
subtype 1 (AT1R) and angiotensin II subtype 2 (AT2R) receptors to exert its functions. 
As the D allele is reported to be more common in migraine (4), and people with 1 or 2 
copies of the D allele tend to have higher ACE activity (16), it is plausible to state that 
ACE probably contributes to migraine pathogenesis. Lisinopril, a drug used in 
prophylactic treatment of migraine is an angiotensin converting enzyme inhibitor. It has 
been shown to be clinically effective in the prevention of migraine attacks (19). The 
pharmacological effects of Lisinopril in migraine may explain ACE’s role in migraine 
pathophysiology. Besides inhibiting the conversion of angiotensin I to angiotensin II, 
Lisinopril also alters sympathetic activity, inhibits free radical activity, increases 
prostacycline synthesis and blocks the degradation of bradykinin, encephalin and 
substance P (22).  
 
Our research team has previously tested the association of MTHFR C677T variant to 
migraine in the Australian Caucasian population (4, 7). We utilised two methods, 
unrelated case-control and family-based case control tests to assess the association. The 
study group included 270 unrelated migraine cases and a matched group of 270 unrelated 
non-migraine controls. The statistical analysis revealed significant overrepresentation of 
the TT genotype in individuals with migraine with aura compared to the control group. 
The TT genotype was found to be a modest risk factor for migraine with aura but not 
migraine without aura. Recently, we investigated the combined effects of ACE and 
MTHFR genotype variants on migraine risk, and the result showed that the presence of the 
MTHFR TT genotype and at least one copy of the ACE D allele was a modest risk factor 
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for migraine susceptibility. The overall finding indicates that MTHFR TT and ACE 
ID/DD genotypes act synergistically to increase migraine with aura susceptibility by 
approximately three-fold (4). Nyholt et al., through genomewide latent-class analysis 
(LCA) in migrainous subjects, identified significant linkage on chromosome 5q21 and 
suggestive linkage on chromosomes 8, 10 and 13. They also identified linkage between 
chromosome 1 and phonophobia, chromosome 5 and pulsating headache, chromosome 6 
with physical activity discomforts and photophobia, nausea/vomiting to chromosome 8, 
chromosome 10 with phonophobia and photophobia and chromosome 13 to photophobia 
(23). This study investigated the broad contribution of chromosomal loci to migraine 
clinical symptoms through linkage analysis, but did not consider the effects of specific 
genes or polymorphisms within genes.  
 
There has been very limited research conducted into the clinical effects of specific 
genotypic polymorphisms in migraine susceptibility. As multiple genes have been shown 
to contribute to migraine susceptibility, it is plausible to assume that different genotypes 
in susceptibility genes may cause varying disease manifestation. This study aimed to 
investigate the endophenotypes involved in two identified migraine susceptibility genes, 
MTHFR and angiotensin converting enzyme ACE. The correlation study examined the 
link between genotype and clinical data, determining whether common polymorphisms of 
these genes were associated with not just migraine in general, but more specifically to 
particular migraine sub-types, symptoms, severity, gender and response to medication. 
These clinical profiles may ultimately assist in prescribing effective, individualised and 
targeted treatment for migraine. 
 
Methods  
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Study subjects and variables 
All subjects included in the study were Caucasians with United Kingdom descent 
recruited from the East Coast of Australia. Participants were required to complete a 
detailed questionnaire, and those suffering from migraine were classified as having 
migraine with aura (MA) or migraine without aura (MO). The diagnosis of migraine was 
based on the International Headache Society (IHS) criteria and confirmed by neurologists 
Dr Peter Brimage and Dr John Macmillan, who interviewed all participants. The 
questionnaires were administered through Griffith University’s Genomic Research Centre 
(GRC). The population subjects were drawn from two large age (+/- 5 years) and sex 
matched case-control panels. For DNA extraction, 20mL of whole blood was collected.  
 
The dependent variables for the study were migraine clinical data related information. 
There were six main types of outcome or dependent variables. These were, “migraine 
subtypes”, “migraine demographics”, “symptoms before, during or just prior to 
migraine”, “migraine triggers”, “treatment and medication”, “smoking” and “alcohol 
intake” (Table 1). Each of the dependent variables underwent a statistical correlation 
study against the genotype. The susceptibility genes, MTHFR and ACE, each have three 
possible genotypes. For MTHFR they are CC, CT and TT; while for ACE they are II, ID 
and DD.  
 
 
The study group consisted of 267 participants with genotyped MTHFR and 250 
participants in the ACE group. Of the 267 participants in the MTHFR group, 100 (37%) 
had the wild-type CC genotype, 135 (51%) were heterozygous (CT) and 32 (12%) had the 
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homozygous TT genotype. There were 38% of phenotyped as having MO and 62% with 
MA. The MTHFR group consisted of 27% males and 73% females. Out of the ACE 
group, 31 (12%) participants had the II genotype, 142 (57%) had the ID genotype and 77 
(31%) had the DD genotype. The group consisted of 70 (28%) males and 180 (72%) 
females. Of the 250 ACE group subjects, 100 (40%) were diagnosed as having MO while 
150 (60%) had the MA diagnosis. Those participants who experienced both subtypes of 
migraine were classed as being affected with MA. Individuals affected with, or having a 
family history of known migraine comorbid conditions such as mental illness and cerebral 
vascular disease were excluded from the study. 
 
Statistical Analysis 
The chi-square test was used to identify differences between one dependant variable and 
one independent variable. It was used for tests of differences between genotype and all 
other variables (excluding quantitative variables), and migraine diagnosis (MO/MA) and 
all other variables. For quantitative outcome variables, nonparametric tests of variance, 
the Kruskal-Wallis, Median, Mann-Whitney and Kolmogorov-Smirnov tests were used. 
The chi-square and non-parametric tests of variance provided a simple framework to 
model the relationship between genotype or MO/MA diagnosis and the large number of 
migraine clinical variables (eg. age of onset of migraines and types of migraine 
symptoms).  
 
Logistic and ordinal regressions were used to devise models where more than one 
independent variable (ie. genotype and gender) was used to predict the outcome 
(dependent) variables. The regression analyses were able to identify whether the addition 
of gender improved the prediction of outcome variables as compared to simply predicting 
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with the genotypes. The statistical tests chosen were suitable for the profiling of MTHFR 
and ACE genotypes and yielded meaningful results in most instances. Consequently, the 
migraine clinical information, symptoms, triggers and treatments were classified 
according to the statistical tests conducted into appropriate genotype, gender and migraine 
diagnosis (MO/MA) groups. All statistical tests were carried out using the SPSS software 
version 13 for windows. The statistical tests were all based on two-sided hypotheses to 
explore all possible correlations.  
 
Results 
 
Analysis of patient variables against MTHFR genotype 
 
As demonstrated in Table 2, the clinical variables that showed statistical significance were 
“Migraine Diagnosis” (p<0.001, df = 2), “Symptoms during or just prior to migraine, 
Unilateral Head Pain” (p = 0.029, df = 2), “Symptoms during or just prior to migraine: 
Physical Activity Discomforts” (p = 0.011, df = 2), and “Migraine triggers, Stress” (p = 
0.026, df = 2); while “Symptoms prior to migraine: Visual Disturbances” showed slight 
statistical significance (p=0.062, df = 2). 94% of individuals with the TT genotype, 
suffered from MA as compared to 61% and 55% of individuals carrying the CC and CT 
genotypes respectively. This had previously been observed in other migraine association 
studies at the GRC (7). Participants carrying the TT genotype experienced the highest 
percentage of visual disturbance prior to a migraine attack, with 78% of individuals with 
the TT genotype affected with the clinical symptom. Another significant clinical variable 
was unilateral head pain, experienced during or just prior to a migraine attack. It appeared 
that individuals carrying one or more copies of the T allele were more prone to unilateral 
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head pain during or just prior to a migraine attack. Within the TT genotype, 87% of 
migraineurs experienced unilateral head pain compared to 62% in the CC group. The CT 
group showed an intermediate percentage of individuals who experienced unilateral head 
pain (77%). A smaller percentage of migraineurs carrying the CC genotype experienced 
discomforts associated with physical activity during or just prior to migraine (69%), 
compared to the CT (88%) and TT (83%) group. This finding suggested that individuals 
carrying one copy of the T allele were more likely to experience discomforts associated 
with physical activity during or just prior to migraine compared to the CC genotype. The 
CT genotype group had the highest percentage of participants acknowledging stress as a 
migraine trigger (76%). The quantitative variables, analysed by the Kruskal-Wallis and 
Median Test with MTHFR genotype as the grouping variable, showed no significant 
difference in median or group locations.  
 
The addition of independent variable “Sex” in a binary logistic regression (dependent 
variable = migraine clinical data; independent variable = “Genotype” & “Sex”), revealed 
statistical significance amongst a number of other migraine symptoms. The reference 
group used, female participants with the TT genotype, were significantly different to other 
gender and genotype groups in “Symptoms during or just prior to migraine: Nausea” (p = 
0.01, OR = 3.41, CI-95 = 1.44-8.08), “Symptoms during or just prior to migraine: 
Osmophobia” (p = 0.03, OR = 3.39, CI-95 = 1.01-10.48), “Symptoms during or just prior 
to migraine: Unilateral Head Pain” (p = 0.01, OR = 0.35, CI-95 = 0.15-0.79), “Symptoms 
during or just prior to migraine: Bilateral Head Pain” (p = <0.001, OR = 0.25, CI-95 = 
0.11-0.55) and “Treatment prescribed, Natural Remedy” (p = 0.04, OR = 0.2, CI-95 = 
0.05-0.92). Females in general were more likely to suffer from nausea and osmophobia 
during or just prior to a migraine attack than men (refer to Table 3). Also, female 
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participants with the TT genotype had the greatest percentage of reported unilateral head 
pain during or just prior to a migraine attack, with all 17 (100%) females with the TT 
genotype who answered the question experiencing the symptom. Table 3 also showed that 
being female and carrying one or more copies of the T allele appeared to be a risk factor 
for experiencing unilateral head pain, as 63% of all females with the CC genotype, 81% 
with the CT genotype and 100% with the TT genotype suffered from unilateral head pain. 
This trend was not observed in male participants, as the percentage of distribution 
between the genotypes in males appeared to be comparatively equal in unilateral head 
pain. Conversely, male subjects experienced higher incidences of bilateral head pain 
compared to female subjects, especially in those with the TT genotype. This was also 
supported by the lower percentage of females with the CT and TT genotype who 
experienced bilateral head pain. Taken together, the T allele appeared to be associated 
with unilateral head pain and not bilateral head pain in females. Of male subjects 2% who 
responded had used natural remedy as a migraine treatment, while female subjects 
reported a percentage of between 15-25%. This information, coupled with the odds ratio 
of 0.2, demonstrated that males were less likely to use natural remedy as a migraine 
treatment.  To test for the contribution of “Sex” (gender) in the quantitative dependent 
variables, ordinal regression was used. The independent variables were “MTHFR 
genotype” and “Sex”. The addition of “Sex” in an ordinal regression showed some 
improvement to the model, but none of the variables tested reached statistical 
significance.  
 
 
 
Analysis of patient variables against re-classified MTHFR genotype 
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To further analyse the contribution of the recessive TT genotype to migraine clinical 
information, the CC and CT groups were reclassified into one group, and compared with 
the TT genotype group. The chi-square, Kruskal-Wallis and Kolmogorov-Smirnov Z tests 
between the two reclassified genotype groups and migraine clinical data revealed 
statistical significance in “Migraine Diagnosis” (p = < 0.001, df = 1), “Symptoms prior to 
migraine: Visual Disturbances” (p = 0.02, df = 1) and “Migraine triggers: Ripe Cheese” 
(p = 0.04, df = 1). The frequency distributions shown in Table  showed that the recessive 
TT genotype group had a significantly higher percentage of individuals with MA, while 
the CC/TT genotype group appeared to be equally distributed in the distribution of the 
type of migraine diagnosis. Visual disturbances prior to a migraine attack showed more 
statistical significance when the genotypes were reclassified (p-value of 0.02 compared to 
the previous p-value of 0.06) in the chi-square analyses. The migraine trigger ripe cheese 
was not previously significant until the genotypes were reclassified. The result revealed 
that the TT genotype was not associated with ripe cheese as a migraine trigger, with no 
subjects with the TT genotype reported ripe cheese as a migraine trigger. 
 
 
To analyse the contribution of “Sex” as a dependent variable in the reclassified genotype 
groups, logistic regression was used. The analysis reached significance in “Symptoms 
during or just prior to migraine: Nausea” (p = 0.01, OR = 3.37, CI-95 = 1.44-7.87), 
“Symptoms during or just prior to migraine: Osmophobia” (p = 0.05, OR = 3.12, CI-95 = 
1.03-9.49), “Symptoms during or just prior to migraine: Unilateral Head Pain” (p = 0.04, 
OR = 0.44, CI-95 = 0.2-0.96), “Symptoms during or just prior to migraine: Bilateral Head 
Pain” (p < 0.01, OR = 0.29, CI-95 = 0.13-0.64), “Treatment effectiveness: 5-HT1 Drugs” 
                                                                                                                 Liu 14
(p = 0.03, OR = 0.07, CI-95 = 0.01-0.82) and mild significance “Treatment: Natural 
Remedy” (p = 0.06, OR = 0.24, CI-95 = 0.05-1.05). The reclassified logistic regression 
model generated similar results to the previous LR model. Female participants had a 
higher rate of reported nausea, osmophobia and unilateral head pain during or just before 
a migraine attack in both models. However, the original LR model appeared to show 
slightly increased significance, especially in “Symptoms during or just prior to migraine: 
Unilateral Head Pain” where the p-value was 0.01 before the genotypes were reclassified 
(p = 0.04 after re-classification). The non-homozygous versus homozygous model yielded 
a new significant variable, “Treatment effectiveness: 5-HT1 Drugs”. It was difficult to 
interpret the results of “Treatment effectiveness: 5 HT-1 Drugs” as only 32 subjects out of 
the 267 in the MTHFR study population group answered the question (Table 5). The 
available data suggested that females in both groups were more likely to find 5-HT1 drugs 
effective in migraine treatment than males. The confounding factor could be that 5-HT 
drugs were prescribed to a lesser extent in the male population.  
 
The ordinal regression of the collapsed genotype, sex and quantitative variables revealed 
significance in cigarette smoking (p = 0.02, df = 2) and mild significance in alcohol 
intake (p = 0.06, df = 2). On examination of the parameter estimates (Table 6), gender 
was a significant factor in both cigarette smoking and alcohol intake. There was a 
decrease in alcohol intake and cigarette smoking from males to females in the reclassified 
group. 
 
 
Analysis of patient variables against ACE genotype 
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The chi-square test between ACE genotype and all other migraine clinical symptom 
variables (qualitative variables only) showed statistical significance in “Migraine triggers: 
Weather Changes” (p = 0.02, df = 2). It appeared that the II genotype group had the 
highest incidence (79%) of eye movement discomforts during or just prior to a migraine 
attack, as compared to the ID (50%) and DD (60%) genotype groups. Individuals with the 
II genotype also reported the highest percentage (42%) of weather change as a migraine 
trigger as compared to the other two ACE genotype groups (Table 7). The Kruskal-Wallis 
and median test revealed no significant differences in population or median location of the 
quantitative variables when grouped by the ACE genotype.  
 
 
With the addition of gender as an independent variable in a binary logistic regression, 
statistical significant results were found in four variables, “Symptoms during or just prior 
to migraine: Nausea” (p = 0.02, OR = 0.35, CI-95 = 0.14-0.84), “Symptoms during or just 
prior to migraine: Osmophobia” (p = 0.05, OR = 0.34, CI-95 = 0.12-0.99), and 
“Symptoms during or just prior to migraine: Bilateral Head Pain” (p = 0.001, OR = 3.843, 
CI-95 = 1.7-8.67). The reference group used was male subjects with the II genotype. This 
was chosen because the D allele was found in previous studies to be transmitted in a 
dominant fashion. None of the quantitative variables examined reached statistical 
significance in the ordinal regression. The female participants had a higher percentage of 
reported nausea during or just prior to migraine across all ACE genotype groups compared 
to the male subjects, with 90% of all females suffering from nausea and only 74% in 
males (Table 8). Being male appeared to be a risk factor for experiencing bilateral head 
pain, once again reinforcing the finding of the MTHFR results, with 66% of male 
participants suffering from the symptom compared to 34% of female participants. 
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Osmophobia during or just prior to migraine was found to not be associated with males 
carrying the ID or DD genotype, with less than 6% of male subjects with the ID and DD 
genotype experiencing the symptom compared to between 27-50% in the other sub-
groups.  
 
 
Analysis of patient variables against re-classified ACE genotype 
 
To examine the dominant inheritance pattern of the D allele, ACE genotypes were 
reclassified as ID/DD and II groups. The chi-square test revealed significance in 
“Symptoms during or just prior to migraine, Eye Movement Discomforts” (p = 0.04, df = 
1) and “Migraine trigger: Weather Changes” (p = 0.03, df = 1). The Mann-Whitney U and 
Two-Sample Kolmogorov Smirnov Test of the quantitative variables demonstrated no 
significant differences in group location or distribution shape between the II/ID and DD 
groups. These results were consistent with previous chi-square analyses of the un-
classified group (ie. II vs ID vs DD). From the frequency distributions (Table 9), the II 
genotype group had a higher percentage (79%) of subjects suffering from eye movement 
discomforts during or just prior to a migraine attack as compared to the subjects with one 
or more copies of the D allele (54%). Similarly, for “Migraine trigger: Weather Change”, 
the II genotype group reported a higher percentage compared to the ID/DD genotype 
group. There appeared to be a greater number of subjects carrying at least one D allele 
using natural remedy as a migraine treatment. However, this variable only showed a 
significance level of 0.068, increasing the probability that this trend occurred by chance. 
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The logistic and ordinal regression analysis of the reclassified genotype groups and sex 
with the other clinical variables (Table 10) revealed significance in “Symptoms during or 
just prior to migraine: Nausea” (p = 0.02, OR = 0.35, CI-95 = 0.14-0.84), “Symptoms 
during or just prior to migraine: Osmophobia” (p = 0.05, OR = 0.34, CI-95 = 0.12-0.99), 
“Symptoms during or just prior to migraine: Bilateral Head Pain” (p = 0.001, OR = 3.85, 
CI-95 = 1.71-8.68). The reference group used was male subjects with the II genotype. The 
gender trend for the reclassified ACE genotypes showed that nausea during or just prior to 
migraine was more common in female than male subjects (86-90% in females versus 63-
77% in males). Male participants with the II genotype had the highest reported cases 
(50%) of osmophobia during or just prior to migraine, while males with the ID/DD 
genotype had the lowest percentage (4%). The distribution of osmophobia incidence in 
females was approximately equal across the II and ID/DD genotype groups (33% and 
28%). This indicated that being male with the II genotype was a risk factor for 
osmophobia. The odds ratio (3.9) for bilateral head pain suggested that male participants 
with the II genotype were approximately 4 times more likely to report bilateral head pain 
as a migraine symptom compared to the other groups. The tendency for more male 
participants suffering from bilateral head pain during or just prior to a migraine attack was 
again obvious, with a total of 66% of males compared to 34% of females suffering from 
the symptom.  
 
 
 
Discussion  
This study investigated the genotype-phenotype correlation of two migraine susceptibility 
genes, MTHFR and ACE, both of which have been implicated in vascular conditions and 
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migraine susceptibility. The study population consisted of 267 subjects in the MTHFR 
group and 250 subjects in the ACE group. The principal methods used in analysis were 
the chi-squared statistic, logistic and ordinal regression and non-parametric analysis of 
variance tests.  
 
This study found that the MTHFR TT genotype was associated with visual disturbance, 
unilateral head pain and physical activity discomforts prior to, during or just before a 
migraine attack, but did not reach the specified statistical significance level. Bilateral head 
pain was statistically significant, and observed more commonly in male participants. On 
the contrary, females, especially with the TT genotype, had the highest reported unilateral 
head pain. It was also observed that bilateral head pain was not associated with females 
carrying the TT genotype. Consequently, unilateral head pain was associated with the 
female gender (especially in the TT and CT group) and bilateral head pain was associated 
with the male gender.  
 
When the MTHFR genotype groups were collapsed into CC & CT together and 
homozygous (TT) groups, the regression models did not improve significantly. Rather, 
the original model (containing all 3 genotypes) appeared to predict outcome variables 
with more accuracy as a whole. This suggests that although the T allele may follow an 
autosomal recessive pattern, the presence of one C677T allele affects migraine clinical 
phenotypes. Most likely, the MTHFR enzyme levels, which are dictated by the 
heterozygous or homozygous states of the C/T alleles, contribute to the phenotypic 
expression of migraine symptoms. As well as intrinsic enzyme levels, individuals with the 
CT genotype, may be more susceptible to environmental triggers for migraine attacks 
compared to individuals with the CC genotype. This scenario is evident in sickle cell 
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anaemia, where heterozygotes usually do not show symptoms of the disease, but with 
appropriate trigger (eg. Hypoxia from high altitude), heterozygotes will exhibit anaemic 
states.  
 
There were few significant associations between ACE genotype and the migraine clinical 
symptoms that reached the required significance level. The ID and DD genotypes were 
found to not be associated with osmophobia, especially in male subjects. The wild-type (II 
genotype) was associated with eye movement discomforts and weather change as a 
migraine trigger. The analyses did not find a significant association between the D allele 
to the diagnosis of migraine without aura as some studies have discovered previously. 
After re-classification of the ACE genotype (into D allele group (ID/DD) and non-D allele 
group (II)), the results gave almost identical association results. This confirms the 
suggestion that the D allele is transmitted in a dominant fashion, as the phenotypes of ID 
and DD genotype group yielded essentially identical results through multiple statistical 
analyses. Interestingly, the re-classification of the D vs non-D allele groups produced only 
modest improvements to the model, suggesting that the D allele may be incompletely 
dominant. No significant link was found between the ACE genotypes and the migraine 
diagnosis of MO, supporting the notion that ACE probably exerts its effect in combination 
with a second migraine susceptibility gene.  
 
As MTHFR and ACE are both implicated in vascular conditions and have been found to 
act synergistically to modulate migraine risk, it is plausible to propose that MTHFR and 
ACE sub-genotypes may also act in combination to alter migraine clinical symptoms, 
severity and response to medication. The MTHFR genotype dictates activity levels of the 
MTHFR enzyme, the main enzyme controlling folic acid synthesis. Folate is a co-factor in 
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the conversion of homocysteine to methionine, and supplementation with folic acid may 
preserve endothelial function in individuals with reduced MTHFR enzyme function. 
Interestingly, the ACE gene is also involved in vascular homeostasis. The ACE enzyme 
plays a role in blood pressure and electrolyte balance regulation and is expressed in 
vascular endothelial cells. As a result of these findings, MTHFR and ACE, especially as a 
combination are plausible migraine susceptibility genes that affect the phenotypic 
expression of migraine disease manifestation and response to medication. 
 
A limitation of this study was that the covariate relationship between MTHFR and ACE 
was not investigated, because of the limited number of suitable participants for the study. 
This covariate relationship was identified previously by Lea et al. at our centre. The study 
discovered that the MTHFR TT genotype plus the presence of one or more copies of the 
ACE D allele, increased migraine susceptibility (4). As the number of cases of migraine 
subjects genotyped for both ACE and MTHFR genes increase in our centre, this analysis 
will be possible in the near future. 
 
Advances in migraine genetic profiling and genotyping make pharmacogenetics, the 
notion of individual prescribing reasonable, as it provides directions for drug companies 
to target migraine drug research. At present, drug prescribing patterns in medical practice 
still in general adhere to the “one size fits all” model. Drugs that cause serious side effects 
in small groups are withdrawn from market, while safe drugs with limited clinical efficacy 
continue to be used. Pharmacogenetic testing, like all other genetic tests, can be carried 
out directly by analysing a person’s DNA (ie. blood samples) or indirectly by examining 
the products of the DNA such as proteins. This type of testing is acceptable to the general 
public provided adequate education (including risks and benefits) is given and informed 
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consent is obtained for the pharmacogenetic test. It is hoped that the result of this study 
will provide impetus to investigate the endophenotype profiles of migraine genes, and for 
pharmaceutical research organisations to implement research studies that targets migraine 
treatment based on a person’s genotype and their associated migraine disease phenotype. 
Ultimately, with the introduction of genotype-specific migraine medication, 
pharmacogenetic testing will be employed as a clinical investigational tool.  
 
This study examined the contribution of the genotypes of two migraine susceptibility 
genes MTHFR and ACE to migraine subtypes, triggers, severity, symptoms and response 
to medication. The TT genotype of the MTHFR gene was found to be associated with the 
largest number of migraine symptoms and triggers. This was expected as the TT genotype 
had been confirmed as a modest risk factor in MA. The ACE sub-genotypes showed no 
statistically significant associations with migraine subtypes, symptoms severity and 
response to medication. This supports the previous finding that ACE does not increase 
migraine susceptibility alone, but may affect migraine risk in the presence of another gene 
such as MTHFR.  The endophenotypic (genetic) profiles developed as part of this research 
study may be useful for designing drugs that specifically target the genes MTHFR and 
ACE. Pharmacogenetic profiling followed by large-scale population studies must be used 
to validate the introduction of a pharmacogenetic test. (5260 words) 
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Table 1: Outcome clinical variables 
 
Variable Group 
 
Example/s 
 
Answers 
 
Variable 
Type 
 
Migraine subtypes 
 
 
Migraine diagnosis 
 
MA 
MO 
 
Qualitative 
Migraine demographics Frequency of migraine attack <1/month 
1-2/month 
3-4/month 
>4/month 
No data 
Quantitative 
(ordinal) 
Symptoms, before during or just prior to migraine Speech problems Yes  
No 
No data 
Qualitative 
Migraine triggers Ripe cheese consumption Yes  
No 
No data 
Qualitative 
Treatment and medication – for migraine Pain killers Yes  
No 
No data 
Qualitative 
Treatment and medication – for other pain Depression Yes  
No 
No data 
Qualitative 
Smoking Number of cigarettes <5/day 
5-<10/day 
10-20/day 
>20/day 
Do not smoke 
Quantitative 
(ordinal) 
Alcohol intake Number of standard drinks <3/day 
3-6/day 
>6/day 
Do not drink 
Quantitative 
(ordinal) 
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Table 2: Frequency distribution of statistically significant clinical variables by genotype, MTHFR * other variables 
    MTHFR genotype  
    CC CT TT 
 
Migraine Diagnosis  MO 39 (39%) 61 (45%) 2 (6%) 
 p = <0.001 MA 61 (61%) 74 (55%) 30 (94%) 
 
Symptoms prior to migraine Yes 36 (52%) 42 (52%) 18 (78%) 
Visual Disturbances 
 p = 0.062 No 33 (48%) 39 (48%) 5 (22%) 
 
Symptoms during or just prior to migraine  Yes 40 (62%) 63 (77%) 20 (87%) 
Unilateral head pain 
p = 0.029 No 25 (38%) 19 (23%) 3 (13%) 
 
Discomforts during or just prior to migraine Yes 51 (69%) 78 (88%) 20 (83%) 
Physical Activity 
p = 0.011 No 23 (31%) 11 (12%) 4 (17%) 
 
Migraine Trigger Yes 42 (61%) 68 (76%) 13 (52%) 
Stress 
p = 0.026 
No 
 
27 (39%) 
 
21 (24%) 
 
12 (48%) 
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Table 3: Frequency distribution of statistically significant clinical variables by sex and genotype, MTHFR 
      MTHFR genotype   
  Sex  CC CT TT Total 
 
Symptoms during or just prior M yes 10 (100%) 15 (60%) 5 (71%) 30 (71%) 
to migraine, Nausea   no 0 (0%) 10 (40%) 2 (29%) 12 (29%) 
p = 0.01, OR = 3.41 (1.44-8.08) F yes 55 (85%) 64 (94%) 16 (89%) 135 (89%) 
    no 10 (15%) 4 (6%) 2 (11%) 16 (11%) 
 
Symptoms during or just prior M yes 1(13%) 3 (14%) 0 (0%) 4 (11%) 
to migraine, Osmophobia   no 7 (88%)  19 (86%) 6 (100%) 32 (89%) 
p = 0.03, OR = 3.39 (1.01-10.48) F yes 15 (26%) 21 (35%) 2 (13%) 38 (29%) 
    no 42 (74%) 39 (65%) 14 (87%) 95 (71%) 
 
Symptoms during or just prior  M yes 4 (50%) 15 (65%) 3 (50%) 22 (60%) 
to migraine, Unilateral Head Pain   no 4 (50%) 8 (35%) 3 (50%) 15 (40%) 
p = 0.01, OR = 0.35 (0.15-0.79) F yes 36 (63%) 48 (81%) 17 (100%) 101 (78%) 
    no 21 (37%) 11 (19%) 0 (0%) 32 (24%) 
 
Symptoms during or just prior  M yes 5 (62%) 13 (62%) 4 (67%) 22 (63%) 
to migraine,  Bilateral Head Pain   no 3 (38%) 8 (39%) 2 (33%) 13 (37%) 
p <0.001, OR = 0.25 (0.11-0.55) F yes 26 (46%) 15 (26%) 3 (19%) 44 (34%) 
    no 31 (54%) 42 (74%) 13 (81%) 86 (66%) 
 
Treatment M yes 0 (0%) 2 (9%) 0 (0%) 2 (5%) 
Natural Remedy    no 8 (100%) 20 (90%) 7 (100%) 35 (95%) 
p = 0.04, OR = 0.2 (0.05-0.92) F yes 8 (15%) 14 (25%) 3 (19%) 25 (20%) 
  
No 
 
47 (85%) 
 
42 (75%) 
 
13 (81%) 
 
102 (80%) 
 
( ) denotes 95% Confidence Interval values 
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Table 4: Frequency distribution of  CC/TT vs TT genotype significant variables 
    MTHFR genotype  
    CC/CT TT 
Migraine Diagnosis MO 100 (43%) 2 (6%) 
  MA 135 (57%) 30 (94%) 
 
Symptoms prior to migraine Yes 78 (52%) 18 (78%) 
Visual Disturbances  No 72 (48%) 5 (22%) 
 
Migraine Trigger Yes 23 (16%) 0 (0%) 
Ripe Cheese 
 
No 
 
124 (84%) 
 
23 (100%) 
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Table 5: Frequency distribution of significant variables from the CC/CT vs TT genotype and sex against other variables logistic 
regression 
      MTHFR genotype   
  Sex  CC/CT TT Total 
 
Symptoms during or just prior to migraine M yes 25 (71%) 5 (71%) 30 (71%) 
Nausea   no 10 (29%) 2 (29%) 12 (29%) 
p = 0.01, OR = 3.37 (1.44-7.87) F yes 119 (90%) 16 (89%) 135 (89%) 
    no 14 (10%) 2 (11%) 16 (11%) 
 
Symptoms during or just prior to migraine M yes 4 (13%) 0 (0%) 4 (11%) 
Osmophobia   no 26 (87%) 6 (100%) 32 (89%) 
p = 0.05, OR = 3.12 (1.03-9.49) F yes 36 (31%) 2 (13%) 38 (29%) 
    no 81 (69%) 14 (87%) 95 (71%) 
 
Symptoms during or just prior to migraine M yes 19 (61%) 3 (50%) 22 (60%) 
Unilateral Head Pain   no 12 (39%) 3 (50%) 15 (40%) 
p = 0.04, OR = 0.44 (0.2-0.96) F yes 84 (72%) 17 (100%) 101 (76%) 
    no 32 (28%) 0 (0%) 32 (24%) 
 
Symptoms during or just prior to migraine M yes 18 (62%) 4 (67%) 22 (63%) 
Bilateral Head Pain   no 11 (38%) 2 (33%) 13 (37%) 
p < 0.01, OR = 0.29 (0.13-0.64) F yes 41 (36%) 3 (19%) 44 (34%) 
    no 73 (64%) 13 (81%) 86 (66%) 
 
Treatment effectiveness M yes 1 (20%) NA& 1 (20%) 
5-HT1 Drugs   no 4 (80%) NA& 4 (80%) 
p = 0.03, OR = 0.07 (0.01-0.82) F yes 17 (77%) 3 (60%) 20 (74%) 
    no 5 (23%) 2 (40%) 7 (26%) 
 
Treatment  M yes 2 (7%) 0 (0%) 2 (5%) 
Natural Remedy   no 28 (93%) 7 (100%) 35 (95%) 
p = 0.06, OR = 0.24 (0.05-1.05) F yes 22 (20%) 3 (19%) 25 (20%) 
  
   
no 
 
89 (80%) 
 
13 (81%) 
 
102 (80%) 
 
& - No participants in this group provided an answered for the question. 
( ) denotes 95% Confidence Interval values 
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Table 6: Ordinal Regression of the CC/CT vs TT genotype and sex against other variables 
  Model Fitting Information 
Quantitative Dependant Variables -2 Log Likelihood Chi-square df p-value 
 
Smoke 43.29 7.451 2 0.024 
Alcohol 
 
 
41.46 
 
 
5.747 
 
 
2 
 
 
0.057 
 
 
Ordinal Regression: Parameter Estimates 
          95% CI 
 Variables Significant Location Estimate df Sig. Upper Lower 
 
Alcohol Intake Sex=1 (Male) -0.362 1 0.020 -0.67 -0.06 
 
Cigarette Smoking 
 
Sex=1 (Male) 
 
-0.466 
 
1 
 
0.011 
 
-0.83 
 
-0.11 
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Table 7: Frequency distribution of statistically significant variables, ACE * other variables 
    ACE genotype  
    II ID DD 
 
Migraine Trigger Yes 8 (42%) 14 (15%) 14 (29%) 
Weather Changes 
 
No 
 
11 (58%) 
 
78 (85%) 
 
34 (71%) 
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Table 8: ACE - Frequency distribution of statistically significant clinical variables by sex and genotype 
     ACE genotype   
  Sex   II ID DD Total  
 
Symptoms during or just prior  M yes 5 (63%) 18 (78%) 9 (75%) 32 (74%) 
to migraine,  Nausea   no 3 (37%) 5 (22%) 3 (25%) 11 (26%) 
p = 0.02, OR = 0.35 (0.14-0.84) F yes 12 (86%) 74 (91%) 37 (88%) 123 (90%) 
    no 2 (14%) 7 (9%) 5 (12%) 14 (10%) 
 
Symptoms during or just prior  M yes 4 (50%) 1 (6%) 0 (0%) 5 (14%) 
to migraine , Osmophobia   no 4 (50%) 17 (94%) 10 (100%) 31 (86%) 
p = 0.05, OR = 0.34 (0.12-0.99) F yes 4 (33%) 19 (27%) 11 (29%) 34 (28%) 
    no 8 (67%) 51 (73%) 27 (71%) 86 (72%) 
 
Symptoms during or just prior  M yes 5 (63%) 11 (65%) 7 (70%) 23 (66%) 
to migraine, Bilateral Head Pain   no 3 (37%) 6 (35%) 3 (30%) 12 (34%) 
p = 0.001, OR = 3.843 (1.7-8.67) F yes 3 (27%) 24 (35%) 13 (35%) 40 (34%) 
    no 8 (73%) 45 (65%) 24 (65%) 77 (66%) 
 
Treatment M yes 0 (0%) 1 (5%) 0 (0%) 1 (3%) 
Natural Remedy    no 8 (100%) 18 (95%) 10 (100%) 36 (97%) 
p = 0.068, OR = 6.77 (0.82-52.78) F yes 0 (0%) 12 (18%) 8 (23%) 20 (18%) 
    
no 
 
10 (100%) 
 
56 (82%) 
 
27 (77%) 
 
93 (82%) 
 
( ) denotes 95% Confidence Interval values 
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Table 9: Frequency distribution of significant chi-square ID/DD vs II group * other variables 
    ACE genotype  
    II ID/DD 
 
Symptoms during or just prior to migraine Yes 15 (79%) 75 (54%) 
Eye Movement Discomforts No 4 (21%) 65 (46%) 
 
Migraine Trigger Yes 8 (42%) 28 (20%) 
Weather Changes 
 
No 
 
11 (58%) 
 
112 (80%) 
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Table 10: Frequency distribution of significant variables from the II vs ID/DD genotype and sex against other variables in logistic 
regression 
     ACE genotype   
  Sex   II ID/DD Total  
 
Symptoms during or just prior to migraine M yes 5 (63%) 27 (77%) 32 (74%) 
Nausea   no 3 (38%) 8 (23%) 11 (26%) 
p = 0.02, OR = 0.35 (0.14-0.84) F yes 12 (86%) 111 (90%) 123 (90%) 
    no 2 (14%) 12 (10%) 14 (10%) 
 
Symptoms during or just prior to migraine M yes 4 (50%) 1 (4%) 5 (14%) 
Osmophobia   no 4 (50%) 27 (96%) 31 (86%) 
p = 0.05, OR = 0.34 (0.12-0.99) F yes 4 (33%) 30 (28%) 34 (38%) 
    no 8 (67%) 78 (72%) 86 (72%) 
 
Symptoms during or just prior to migraine M yes 5 (63%) 18 (67%) 23 (66%) 
Bilateral Head Pain   no 3 (38%) 9 (33%) 12 (34%) 
p > 0.01, OR = 3.85 (1.71-8.68) F yes 3 (27%) 37 (35%) 40 (34%) 
    
no 
 
8 (73%) 
 
69 (65%) 
 
77 (66%) 
 
( ) denotes 95% Confidence Interval values 
 
